Bioequivalence of levothyroxine tablets administered to a target population in steady state

Pharmacological Research

Volumn 39, Issue 3, 1999, Pages 193-201

  Cerutti, Renata ^a   Rivolta, Giovanni ^a   Cavalieri, Livio ^a   Di Giulio, Claudia ^a   Grossi, Enzo ^a   Vago, Tarcisio ^b   Baldi, Gabriella ^b   Righini, Velella ^b   Marzo, Antonio ^c  

^a Bracco SpA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c IPAS SA   (Switzerland)

Author keywords

Bioequivalence; Levothyroxine; Levotriiodothyronine; Serum concentration; Thyroid hormones

Indexed keywords

DRUG METABOLITE; LEVOTHYROXINE; LEVOTHYROXINE SODIUM; LIOTHYRONINE; THYROID HORMONE; THYROXINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BRONCHITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CYSTITIS; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; FREE THYROXINE INDEX; HUMAN; HYPERTENSION; HYPOTHYROIDISM; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; STATISTICS; TABLET; THYROXINE BLOOD LEVEL;

EID: 0033105448     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1998.0426     Document Type: Article

References (20)

1. Kendall EC. The isolation in crystalline form of the compound containing iodine which occurs in the thyroid: Its chemical nature and physiological activity. Trans Assoc Am Physicians 1915; 30: 420-49.
2. Harington CR, Barger G. Thyroxine. III. Constitution and synthesis of thyroxine. Biochem J 1927; 21: 169-83.
3. Harington CR. Chemistry of thyroxine: Isolation of thyroxine from thyroid gland. Biochem J 1926; 20: 293-9.
4. Gross J, Pitt-Rivers R. The identification of 3:5:3′-L-triiodothyronine in human plasma. Lancet 1952; i: 439-41.
5. Gross J, Pitt-Rivers R. 3:5:3′-L-triiodothyronine. 1. Isolation from thyroid gland and synthesis. 2. Physiological activity. Biochem J 1953; 53: 645-57.
6. Gottwald R, Lorkowski G, Petersen G, Schnitzler M, Lücker PW. Bioequivalence of two commercially available levothyroxine-Na preparations in athyreotic patients. Meth Find Exp Clin Pharmacol 1994; 16: 645-50.
7. Hennessey JV, Burman KD, Wartofsky L. The equivalency of two L-thyroxine preparations. Ann Intern Med 1985; 102: 770-3.
8. Rennie D. Editorial: Thyroid storm. J Am Med Assoc 1997; 277: 1238-43.
9. Spigelman MK. Bioequivalence of levothyroxine preparations for treatment of hypothyroidism. J Am Med Assoc 1997; 277: 1199-200.
10. Dong BJ, Hauck WW, Gambertoglio JG, Gee L, White JR, Bubp JL, Greenspan FS. Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. J Am Med Assoc 1997; 277: 1205-13.
11. Eckert CH. Bioequivalence of levothyroxine preparations: Industry sponsorship and academic freedom. J Am Med Assoc 1997; 277: 1200-01.
12. CPMP working party on efficacy of medicinal products. Note for guidance: Investigation of bioavailability and bioequivalence. III/54/89-EN, FINAL, December 1991.
13. In vivo Bioequivalence Guidances/General Information. United States Pharmacopoeia 1993; 23: 1929-32.
14. Marzo A. Pharmacokinetic analysis, bioavailability and operating guidelines. J Pharm Pharmacol 1997; 49: 1259-60.
15. Marzo A, Balant LP. Bioequivalence: An updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products. Arzneim Forsch 1995; 45: 109-15.
16. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-80.
17. Marzo A, Rescigno A. Pharmacokinetics of endogenous substances: Some problems and some solutions. Eur J Drug Metab Pharmacokinet 1993; 18: 77-88.
18. Grizzle JE. The two-period change-over design and its use in clinical trials. In: Crossover Trials in Clinical Research. Senn S ed. New York: John Wiley and Sons, 1993: 467-80.
19. Marzo A. Clinical pharmacokinetic registration file for NDA and ANDA procedures. Pharmacol Res 1997; 36: 425-50.
20. Marzo A. Open questions in bioequivalence. Pharmacol Res 1995; 32: 237-40.